VEA
CRSP icon

Virtus ETF Advisers’s CRISPR Therapeutics CRSP Stock Holding History

Virtus ETF Advisers’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,702
Closed -$303K – 514
2024
Q4 		$303K Buy
7,702
+2,655
+53% +$125K 0.12% 245
2024
Q3 		$237K Hold
5,047
– – 0.11% 242
2024
Q2 		$273K Sell
5,047
-1,007
-17% -$58.2K 0.13% 239
2024
Q1 		$413K Buy
6,054
+871
+17% +$62.4K 0.22% 191
2023
Q4 		$324K Buy
5,183
+3,502
+208% +$194K 0.21% 213
2023
Q3 		$76.3K Sell
1,681
-163
-9% -$8.42K 0.05% 369
2023
Q2 		$104K Sell
1,844
-173
-9% -$9.82K 0.06% 365
2023
Q1 		$91.2K Sell
2,017
-774
-28% -$37.6K 0.05% 358
2022
Q4 		$113K Buy
2,791
+996
+55% +$52.8K 0.06% 432
2022
Q3 		$117K Buy
1,795
+11
+0.6% +$797 0.05% 402
2022
Q2 		$108K Sell
1,784
-297
-14% -$17.5K 0.04% 413
2022
Q1 		$131K Sell
2,081
-122
-6% -$7.66K 0.06% 247
2021
Q4 		$167K Buy
2,203
+559
+34% +$48.8K 0.06% 299
2021
Q3 		$184K Sell
1,644
-93
-5% -$11.7K 0.08% 292
2021
Q2 		$281K Sell
1,737
-266
-13% -$32.4K 0.12% 203
2021
Q1 		$244K Buy
2,003
+37
+2% +$5.59K 0.1% 293
2020
Q4 		$301K Sell
1,966
-3,189
-62% -$377K 0.12% 209
2020
Q3 		$431K Sell
5,155
-689
-12% -$61.1K 0.23% 154
2020
Q2 		$429K Buy
5,844
+347
+6% +$20.3K 0.2% 172
2020
Q1 		$233K Sell
5,497
-809
-13% -$41.8K 0.1% 262
2019
Q4 		$384K Buy
+6,306
New +$344K 0.06% 273

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Virtus ETF Advisers's CRSP Position: Q1 2025 in Review

Virtus ETF Advisers sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 7,702 shares — an estimated $303K sold.

Virtus ETF Advisers first reported a position in CRSP in Q4 2019 and held it in 21 quarters. The position peaked at $431K in Q3 2020. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

  • Virtus ETF Advisers reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 7,702 CRISPR Therapeutics shares in Q1 2025, an estimated $303K.
  • Virtus ETF Advisers first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 21 quarters.
  • Virtus ETF Advisers's CRISPR Therapeutics position peaked at $431K in Q3 2020.
  • 396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.